Eculizumab regulatory update

The U.K.’s NICE issued final guidance recommending Orphan drug Soliris eculizumab from Alexion to treat atypical hemolytic uremic syndrome (aHUS). The recommendation is the first under the agency’s highly specialized technology program. The guidance is in line with a final appraisal determination (FAD) and contingent on measures to reduce the drug’s impact on NHS’s budget (see BioCentury, Jan. 5). ...